teniposide (vumon) Report issue

Small molecule Orphan Drug FDA Approved FDA Priority Review FDA
AACT ChEMBL DrugBank Drug Central Drugs@FDA KEGG MeSH PubChem repoDB

Active Ingredient History

NOW
  • Now
Teniposide is an inhibitor of topoisomerase II with anti-cancer activity. The drug was approved by FDA under the name Vumon for the treatment of children with acute lymphoblastic leukemia.   NCATS

Chemistry

  • SMILES: COC1=CC(=CC(OC)=C1O)[C@H]2[C@@H]3[C@H](COC3=O)[C@H](O[C@@H]4O[C@@H]5CO[C@H](O[C@H]5[C@H](O)[C@H]4O)C6=CC=CS6)C7=C2C=C8OCOC8=C7
  • InChIKey: NRUKOCRGYNPUPR-QBPJDGROSA-N
  • Mol. Mass: 656.654
  • ALogP: 2.75
  • ChEMBL Molecule:
    teniposide  
More Chemistry

Pharmacology

Drug Pricing (per unit)

United States

$150.0100
More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

Alternative names

4'-demethylepipodophyllotoxin 9-(4,6-o-(r)-2-thenylidene-beta-d-glucopyranoside) | 4'-demethylepipodophyllotoxin 9-(4,6-o-(r)-ethylidene-beta-d-glucopyranoside) | epidophyllotoxin | teniposid | teniposide | téniposide | teniposido | teniposidum | tenoposide | vm26 | vm-26 | vumon

Organizations (13)

Research & Development (11)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (2)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (6)

Approved Indications (1)


 

Precursor Cell Lymphoblastic Leukemia-Lymphoma (approved 1992)

Experimental Indications - Clinical Trial Phases 1-4 (6)


 

Leukemia (Phase 2)

Leukemia, Lymphocytic, Chronic, B-Cell (Phase 4)

Lymphoma (Phase 4)

Lymphoma, Large-Cell, Immunoblastic (Phase 2)

Precursor B-Cell Lymphoblastic Leukemia-Lymphoma (Phase 2)

Precursor Cell Lymphoblastic Leukemia-Lymphoma (Phase 4)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 14
  • # of Trial Organizations: 11

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue